Financial Performance - Mobile Infrastructure Corporation reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, representing an earnings surprise of -10.00% [1] - The company posted revenues of $8.99 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.24%, and down from $9.27 million a year ago [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Performance - Shares of Mobile Infrastructure Corporation have declined approximately 15.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $10.39 million, and for the current fiscal year, it is -$0.32 on revenues of $38.17 million [7] - The trend of estimate revisions for Mobile Infrastructure Corporation was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Real Estate - Operations industry, to which Mobile Infrastructure Corporation belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

分组1 - Inspirato Incorporated reported a quarterly loss of $0.42 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.41, but an improvement from a loss of $2.25 per share a year ago, indicating a significant year-over-year recovery [1] - The company posted revenues of $63.11 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 10.19%, although this represents a decline from $67.38 million in the same quarter last year [2] - Over the last four quarters, Inspirato has surpassed consensus EPS estimates two times and revenue estimates three times, showcasing some level of operational resilience [2] 分组2 - The stock has underperformed, losing about 6.1% since the beginning of the year, while the S&P 500 has gained 8.4%, indicating a challenging market environment for the company [3] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $64.74 million, and for the current fiscal year, it is -$1.00 on revenues of $245.03 million, reflecting cautious expectations moving forward [7] - The Leisure and Recreation Services industry, to which Inspirato belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, suggesting a challenging industry outlook that could impact stock performance [8]

Group 1: Earnings Performance - CAE reported quarterly earnings of $0.15 per share, matching the Zacks Consensus Estimate, and consistent with earnings from the previous year [1] - The company posted revenues of $793.98 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.99%, but showing an increase from $783.87 million year-over-year [2] - Over the last four quarters, CAE has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2][3] Group 2: Stock Performance and Outlook - CAE shares have increased approximately 13.3% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $852.69 million, and for the current fiscal year, it is $0.97 on revenues of $3.56 billion [7] Group 3: Industry Context - The Aerospace - Defense Equipment industry, to which CAE belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact CAE's stock performance [5][6]

Group 1 - Lineage Cell (LCTX) reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.03 per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $2.77 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 75.00%, compared to year-ago revenues of $1.41 million [2] - Lineage Cell shares have increased approximately 101% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] Group 2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Lineage Cell was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $2.52 million, and -$0.09 on revenues of $7.94 million for the current fiscal year [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Lineage Cell belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Biofrontera Inc. (BFRI), is expected to report a quarterly loss of $0.45 per share, reflecting a year-over-year change of +59.8%, with revenues anticipated to be $8.2 million, up 4.6% from the previous year [9]

Core Viewpoint - York Water (YORW) reported quarterly earnings of $0.35 per share, exceeding the Zacks Consensus Estimate of $0.33 per share, with a year-over-year comparison showing no change in earnings [1][2] Financial Performance - The company achieved revenues of $19.2 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.05%, compared to $18.75 million in the same quarter last year [2] - Over the last four quarters, York Water has exceeded consensus EPS estimates only once [2] Stock Performance - York Water shares have declined approximately 5.5% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.41 on revenues of $21 million, and for the current fiscal year, it is $1.33 on revenues of $78 million [7] - The trend of estimate revisions for York Water was mixed prior to the earnings release, which may change following the recent report [6] Industry Context - The Utility - Water Supply industry, to which York Water belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Performance - TScan Therapeutics reported a quarterly loss of $0.28 per share, consistent with the Zacks Consensus Estimate, and unchanged from a year ago [1] - The company posted revenues of $3.08 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 58.07%, compared to $0.54 million in the same quarter last year [2] - Over the last four quarters, TScan has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Performance - TScan Therapeutics shares have declined approximately 47% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $2.38 million, and for the current fiscal year, it is -$1.11 on revenues of $9.67 million [7] - The estimate revisions trend for TScan was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which TScan belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact TScan's stock performance [5]

Core Insights - Rapid Micro Biosystems, Inc. reported a quarterly loss of $0.27 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.26, but an improvement from a loss of $0.29 per share a year ago [1] - The company posted revenues of $7.26 million for the quarter, missing the Zacks Consensus Estimate by 0.52%, but showing growth from $6.62 million in the same quarter last year [2] - The stock has increased by approximately 262.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The earnings outlook for Rapid Micro Biosystems is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.25 on revenues of $9.1 million, and for the current fiscal year at -$0.98 on revenues of $33.1 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Rapid Micro Biosystems belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Core Viewpoint - Xometry (XMTR) is experiencing solid improvement in earnings estimates, which is likely to positively impact its stock price in the near term [1][2]. Earnings Estimates - Analysts are increasingly optimistic about Xometry's earnings prospects, leading to higher estimates that should reflect in the stock price [2]. - The consensus earnings estimate for the current quarter is $0.11 per share, indicating a year-over-year increase of +450.0% [5]. - For the full year, the earnings estimate has risen to $0.35 per share, representing a change of +975.0% from the previous year [6]. Estimate Revisions - Over the past 30 days, the Zacks Consensus Estimate for Xometry has increased by 5%, with one estimate moving higher and no negative revisions [5]. - The consensus estimate for the current year has increased by 18.63%, with three estimates moving higher and no negative revisions [6][7]. Zacks Rank - Xometry has earned a Zacks Rank 2 (Buy) due to promising estimate revisions, which indicates a favorable investment opportunity [8]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [8]. Stock Performance - Xometry's stock has increased by 29.5% over the past four weeks, driven by strong estimate revisions and investor interest [9].

Core Viewpoint - ITT has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [2][4]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade for ITT suggest an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [5][10]. Earnings Estimate Revisions for ITT - For the fiscal year ending December 2025, ITT is expected to earn $6.48 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 2.1% over the past three months [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - The upgrade of ITT to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Xeris Biopharma (XERS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power ...